SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

SAN

84.64

-0.96%↓

MRK1

119.5

-0.29%↓

SHL.DE

42.55

+0.59%↑

ARGX

791.4

-0.53%↓

PHIA

22.7

-5.73%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

18.7 6.01

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.58

Max

18.74

Põhinäitajad
By Trading Economics
Sissetulek	41M -5.4M
Müük	48M 27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	46M 1.1M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+29.07% upside

Turustatistika
By TradingEconomics
Turukapital	-49M 858M
Eelmine avamishind	12.69
Eelmine sulgemishind	18.7

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. dets 2025, 23:21 UTC

Tulu

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. dets 2025, 23:14 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. dets 2025, 22:01 UTC

Suurimad hinnamuutused turgudel

Costco Wholesale Reports Higher Monthly Sales

3. dets 2025, 21:38 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. dets 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. dets 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. dets 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. dets 2025, 23:10 UTC

Tulu

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. dets 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. dets 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5M

3. dets 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. dets 2025, 22:20 UTC

Tulu

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. dets 2025, 22:19 UTC

Tulu

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. dets 2025, 22:17 UTC

Tulu

Salesforce Working to Add Voice to Agentforce, CEO Says

3. dets 2025, 22:16 UTC

Tulu

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. dets 2025, 22:15 UTC

Tulu

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. dets 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. dets 2025, 21:49 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:23 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. dets 2025, 21:19 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:06 UTC

Tulu

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:04 UTC

Tulu

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. dets 2025, 21:04 UTC

Tulu

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. dets 2025, 21:03 UTC

Tulu

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

29.07% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 29.07%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.